search
  • Exploring Darbepoetin Alfa Potential Versus Epoetin Beta

Exploring Darbepoetin Alfa Potential Versus Epoetin Beta

Darbepoetin’s extended half-life allows for less frequent dosing to both raise and sustain hemoglobin levels.2

Change for Better...Change to

Abbreviations ▼

CKD: Chronic kidney disease; ESA: Erythropoiesis-stimulating agent; Hb: Hemoglobin.

References ▼

1. Carrera F, Burnier M. Use of darbepoetin alfa in the treatment of anaemia of chronic kidney disease: Clinical and pharmacoeconomic considerations. NDT Plus. 2009;2(Suppl_1):i9–i17. 2. Agarwal AK. Darbepoetin alfa for anemia in chronic kidney disease. Expert Rev Clin Pharmacol. 2008;1(3):369–379.

 

LMRC Code: GGI-CO-A1-AQS-DCVN-BANNERS-I23-0349

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Cresp 2

Cresp®(Biosimilar of darbepoetin alpha), a product by Dr. Reddy's is an erythropoiesis-stimulating agent which helps in treatment of renal anemia in pre-dialysis patients

Cresp

Related Articles

Understanding Immunoglobulin A Nephropathy: From Multi-Hit Theory to Genetic Blueprint

Explore the complex pathogenesis of Immunoglobulin A nephropathy through the Multi-Hit Theory and discover how...

Advancing Care in Transplantation and ESA Resistance: Insights and Solutions

A comprehensive analysis of the evolving landscape of kidney disease treatments, focusing on xenotransplantation advancements...

Latest Advancements for Hyperkalemia Therapeutics in Non-Dialysis Chronic Kidney Disease

Stay informed about the latest therapeutic options for managing hyperkalemia in non-dialysis CKD.

Updates on New Therapies for Patients with CKD

Explore the latest therapies, including ARNI and finerenone, proven to slow CKD progression and protect...

Keep Up to Date: Discover the KDIGO 2024 Guidelines for CKD Management!

Learn the latest KDIGO recommendations for evaluating CKD risk in adults and managing stages G3-G5

Compassion in Healthcare

ICML Revisited 2

Fondaparinux sodium vs. low-molecular-weight heparin in preventing deep vein thrombosis in patients undergoing hip replacement surgery

Impact of etranacogene dezaparvovec on the quality of life of individuals with severe and moderately severe hemophilia B

The comparison between oral arsenic plus imatinib and imatinib alone for the treatment of newly diagnosed chronic myeloid leukemia

Efficacy and safety of etranacogene dezaparvovec gene therapy for haemophilia B

Enhanced health-related quality of life with ide-cel in relapsed and refractory multiple myeloma patients